SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Qiu Li · Study

Home/Author

Qiu Li

3 works· latest 2021· 1 institutionscluster: provisionalORCID 0000-0002-5299-9050

h-index3

i103

Citations189

Works here3

19

20

21

Most cited in this library

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states2021 · 83 citations
Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma2020 · 53 citations
Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma2019 · 53 citations

Works

3 shown

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International·2021·5 authors

83citations

Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma

Future Oncology·2020·2 authors

53citations

Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma

Liver International·2019·6 authors·Open access

53citations